Powder: -20°C for 3 years | In solvent: -80°C for 1 year
3CAI 是特异性的AKT1和AKT2抑制剂。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
1 mg | ¥ 209 | 现货 | ||
2 mg | ¥ 293 | 现货 | ||
5 mg | ¥ 478 | 现货 | ||
10 mg | ¥ 687 | 现货 | ||
25 mg | ¥ 1,230 | 现货 | ||
50 mg | ¥ 2,150 | 现货 | ||
100 mg | ¥ 2,950 | 现货 | ||
200 mg | ¥ 4,350 | 现货 | ||
500 mg | ¥ 6,770 | 6-8周 | ||
1 mL * 10 mM (in DMSO) | ¥ 528 | 现货 |
产品描述 | 3CAI is a potent and specific AKT1 and AKT2 inhibitor which showed significant inhibition of AKT in an in vitro kinase assay and suppressed expression of AKT direct downstream targets such as mTOR and GSK3β as well as induced growth inhibition and apoptosis in colon cancer cells. |
体外活性 | 3CAI is a potential inhibitor of AKT and is a much more potent AKT1 inhibitor than PI3K (60% inhibition at 1 vs 10 μM, respectively). HCT116 and HT29 colon cancer cells are seeded on 6 cm dishes in 1% FBS/McCoy's 5A (HCT116) with 3CAI (4 μM), I3C or the AKT inhibitor and then incubated for 4 days. Results show that the number of apoptotic cells is significantly increased by 3CAI in HCT116 and HT29 colon cancer cells compared with untreated control cells[1]. AKT-mediated phosphorlyation site of mTOR (Ser2448) and GSK3β (Ser9) are substantially decreased by 3CAI in a time-dependent manner. Moreover, pro-apoptotic marker proteins p53 and p21 are also upregulated by 3CAI after 12 or 24 h of treatment. The effect of 3CAI on the kinase activities of AKT1, MEK1, JNK1, ERK1 and TOPK is tested using in vitro kinase assays based on these screening data. The results show that 3CAI (1 μM) suppresses only AKT1 kinase activity and the other kinases tested are not affected by 3CAI. 3CAI substantially suppresses AKT1 activity as well as AKT2 activity in a dose dependent manner. 3CAI inhibits down-stream targets of AKT and induces apoptosis. |
体内活性 | HCT116 cancer cells are injected into the right flank of individual athymic nude mice. Mice are orally administered 3CAI at 20 or 30 mg/kg, I3C at 100 mg/kg, or vehicle 5 times a week for 21 days, to examine the antitumor activity of 3CAI in vivo. Expression of these AKT-target proteins is strongly suppressed by 30 mg/kg of 3CAI in tumor tissues[1]. Treatment of mice with 30 mg/kg of 3CAI significantly suppresses HCT116 tumor growth by 50% relative to the vehicle-treated group (p<0.05). Remarkably, mice seem to tolerate treatment with these doses of 3CAI without overt signs of toxicity or significant loss of body weight compared with vehicle-treated group. |
分子量 | 193.63 |
分子式 | C10H8ClNO |
CAS No. | 28755-03-5 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 246 mg/mL (1270.46 mM), Sonication is recommended.
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
DMSO | 1 mM | 5.1645 mL | 25.8224 mL | 51.6449 mL | 129.1122 mL |
5 mM | 1.0329 mL | 5.1645 mL | 10.329 mL | 25.8224 mL | |
10 mM | 0.5164 mL | 2.5822 mL | 5.1645 mL | 12.9112 mL | |
20 mM | 0.2582 mL | 1.2911 mL | 2.5822 mL | 6.4556 mL | |
50 mM | 0.1033 mL | 0.5164 mL | 1.0329 mL | 2.5822 mL | |
100 mM | 0.0516 mL | 0.2582 mL | 0.5164 mL | 1.2911 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
3CAI 28755-03-5 Cytoskeletal Signaling PI3K/Akt/mTOR signaling Akt Inhibitor inhibit Protein kinase B PKB inhibitor